Mirapex Patent Expiration

Mirapex is a drug owned by Boehringer Ingelheim. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 16, 2018. Details of Mirapex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6001861 Use of pramipexole in the treatment of restless legs syndrome
Jan, 2018

(6 years ago)

Expired
US6194445 Use of pramipexole in the treatment of restless legs syndrome
Jan, 2018

(6 years ago)

Expired


FDA has granted several exclusivities to Mirapex. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Mirapex, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Mirapex.

Exclusivity Information

Mirapex holds 1 exclusivities. All of its exclusivities have expired in 2014. Details of Mirapex's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
M(M-104) May 13, 2014

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Mirapex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mirapex's family patents as well as insights into ongoing legal events on those patents.

Mirapex's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Mirapex's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 16, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Mirapex Generics:

Pramipexole Dihydrochloride is the generic name for the brand Mirapex. 24 different companies have already filed for the generic of Mirapex, with Heritage Pharma Avet having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Mirapex's generic

How can I launch a generic of Mirapex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Mirapex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Mirapex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Mirapex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.125 mg, 0.5 mg, 1 mg and 1.5 mg 24 Jun, 2005 1 19 Feb, 2008 25 Mar, 2011 Eligible
0.25 mg 27 May, 2005 1 19 Feb, 2008 25 Mar, 2011 Eligible
0.75 mg 31 Jul, 2008 1 09 Apr, 2010 08 Oct, 2010 Extinguished Eligible

Alternative Brands for Mirapex

Mirapex which is used for treating moderate to severe primary Restless Legs Syndrome (RLS)., has several other brand drugs using the same active ingredient (Pramipexole Dihydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Boehringer Ingelheim
Mirapex Er


Apart from brand drugs containing the same ingredient, some generics have also been filed for Pramipexole Dihydrochloride, Mirapex's active ingredient. Check the complete list of approved generic manufacturers for Mirapex





About Mirapex

Mirapex is a drug owned by Boehringer Ingelheim. It is used for treating moderate to severe primary Restless Legs Syndrome (RLS). Mirapex uses Pramipexole Dihydrochloride as an active ingredient. Mirapex was launched by Boehringer Ingelheim in 1997.

Approval Date:

Mirapex was approved by FDA for market use on 01 July, 1997.

Active Ingredient:

Mirapex uses Pramipexole Dihydrochloride as the active ingredient. Check out other Drugs and Companies using Pramipexole Dihydrochloride ingredient

Treatment:

Mirapex is used for treating moderate to severe primary Restless Legs Syndrome (RLS).

Dosage:

Mirapex is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
0.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL
0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL